Latka logo

2024 Revenue

$2M

Customers

150

Funding

$0

Avg ACV

$13.3K

Team

85

Founded

2018

Drug Hunter Revenue (2024)

Drug Hunter generated $2M in revenue in 2024.

Drug Hunter™ is a vital subscription platform that streamlines drug discovery for R&D innovators by consolidating strategies, tactics, and industry knowledge from myriad sources into a searchable database. Managed by a team of industry scientists, it provides distilled insights to enhance decision-making and address discovery challenges. Serving over 150 institutions globally, including leading pharma and biotech companies, investors, and nonprofits, Drug Hunter is an indispensable resource for turning molecules into medicines.

Last updated

Drug Hunter Revenue

In 2024, Drug Hunter's revenue reached $2M.

Drug Hunter Revenue GrowthReported revenue / ARR over time$0$500K$1M$1.5M$2M$2.5M2018201920202021202220232024$0$2MSource: GetLatka.com
YearMilestoneSource
2024Drug Hunter Hit $2m revenue in May 2024Not recorded
2018Launched with $0 revenue

Drug Hunter Valuation, Funding Rounds

We do not have funding information about Drug Hunter yet.

No funding has been reported for Drug Hunter yet.

Customers

Drug Hunter serves 150 customers.

Drug Hunter Employees & Team Size

Drug Hunter employs approximately 85 people as of 2026. It serves 150 customers that rely on its solutions.

Drug Hunter Team GrowthReported headcount over time0204060801002018201920202021202220232024008585Source: GetLatka.com
YearMilestoneSource
2024Reached 85 employees (June 2024)Not recorded

Frequently Asked Questions about Drug Hunter

What is Drug Hunter's revenue?

As of 2024, Drug Hunter generated $2M in revenue.

Who founded Drug Hunter?

Drug Hunter was founded by Dennis Hu.

Who is the CEO of Drug Hunter?

The CEO of Drug Hunter is Dennis Hu.

How many employees does Drug Hunter have?

As of 2024, Drug Hunter had 85 employees.

Where is Drug Hunter headquartered?

Drug Hunter is headquartered in Palo Alto, California, United States.

Data and Sources

All figures on this page are taken directly from interviews or are estimates from public sources and proprietary models. Not financial advice. Read full disclaimer.

Claim this profile